| Business Summary | | GenVec,
Inc.
develops
gene-based
products
that
cause
medically
beneficial
proteins
to
be
produced
at
the
site
of
disease.
Local
production
of
proteins
over
a
sustained
period
may
allow
the
proteins
to
have
a
potential
benefit,
while
minimizing
the
overall
toxicity
that
can
occur
when
large
doses
of
a
protein
are
introduced
directly
into
the
body.
The
Company's
areas
of
focus
are
diseases
of
the
heart
and
blood
vessels,
cancer
and
diseases
of
the
eye.
The
Company
is
developing
products
consisting
of
genes
and
vehicles,
called
vectors,
which
deliver
those
genes
into
cells
at
the
site
of
the
disease.
The
Company
has
specialized
in
the
use
and
improvement
of
particular
types
of
vectors
called
adenovectors.
These
vectors
are
derived
from
adenoviruses,
which
are
viruses
that
cause
ailments
such
as
the
common
cold.
The
Company's
adenovector
technology
allows
it
to
test
the
therapeutic
benefit
of
genes
in
a
broad
range
of
animal
models
of
human
disease. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GenVec,
Inc.
develops
gene-based
products
that
cause
the
production
of
therapeutic
proteins
at
the
site
of
disease,
with
a
current
focus
on
cardiovascular
disease,
oncology
and
ophthalmology.
For
the
six
months
ended
6/30/01,
total
revenues
fell
52%
to
$4.1
million.
Net
loss
totaled
$7
million,
up
from
$2.1
million.
Results
reflect
reduced
amounts
earned
under
the
research
support
agreement
with
Pfizer
and
increased
general
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Herbert Conrad, 68 Chairman | -- | Paul Fischer, Ph.D., 51 Pres,
CEO, Director | $310K | Jeffrey Church, 44 CFO,
Treasurer, Sec. | 226K | Thomas Smart, 37 Sr.
VP, Corp. Devel. | 218K | C. Richter King, Ph.D, 46 VP,
Research | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|